Pertuzumab, another therapeutic HER2/neu+ antibody which targets a different epitope than Trastuzumab and is also approved for treatment of HER2/neu+ breast cancer [25] has been reported to exert additive effects with regard to ADCC when combined with Trastuzumab [36]. Here, ERBB2 is linked to breast cancer.